Adaptyv API
Programmatic access to automated wet-lab for AI agents and workflows
Api · Api OnlyCompany source
Company profile
About Adaptyv Bio
Adaptyv Bio is a biotechnology company that operates a state-of-the-art automated laboratory for protein validation and characterization. The company provides experimental testing services specifically designed for AI-first protein engineering workflows, enabling researchers to validate computationally designed proteins with unprecedented speed and scale. Through their cloud-based platform, protein designers can submit sequences digitally and receive comprehensive experimental data including binding affinity measurements, expression levels, and thermostability assessments in as little as 2-3 weeks. Adaptyv's mission is to make proteins easier to engineer by providing the experimental infrastructure needed to close the loop between computational design and wet-lab validation. Their fully automated laboratory uses high-throughput cell-free expression systems, advanced robotics, and standardized assays to generate clean, consistent data suitable for training machine learning models. The platform serves as a 'lab-in-the-loop' solution, allowing protein design teams to rapidly iterate through multiple rounds of design, build, test, and learn cycles. The company offers transparent per-protein pricing starting from $49 for expression testing and $149 for binding assays, with comprehensive API access for programmatic experiment management. Adaptyv has validated thousands of proteins for leading protein design teams worldwide and maintains Proteinbase, an open repository of experimental protein design data. Founded by Julian Englert (CEO) and Daniel Nakhaee-Zadeh (CTO), the company is headquartered at the Biopole Life Science Campus in Lausanne, Switzerland.
Company description Adaptyv Bio official website
Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Company presenceX
Work at Adaptyv Bio?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Alzheimer's disease (TREM2 target)
- Cancer (EGFR target)
- FGF-1 optimization
- Immunology (IL-7Ra target)
Who it serves
- Academic research labs
- AI protein design teams
- Biotech companies
- Computational biology groups
- Pharmaceutical companies
Deployment & integration
Api Only · Cloud Saas deployment with recorded integration context.
Recorded integration context: API for programmatic access, Benchling, Model Context Protocol (MCP) for AI agents.
Geographic context
MarketsGlobal · Switzerland · United States
Company sourceOfficial website
Company milestones
Platform expansion
May 2026: Released results from muni × Adaptyv TREM2 hackathon with AI agents vs humans; May 2026: Launched Benchling integration for direct ordering; April 2026: Released Adaptyv API for programmatic lab access; September 2025: Launched Proteinbase open protein data repository; September 2025: Opened platform to public access
Partnerships
Recorded partners
- Benchling (Direct Ordering Partners)
- Microsoft Research
- muni (AI agent platform)
- University of Pennsylvania Programmable Biology Group
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Adaptyv Foundry Platform
The cloud lab for protein designers - sequence to experimental data in under 3 weeks
Platform · Cloud SaaSCompany source
Benchling Integration
Direct protein testing from Benchling workflows
Software · Api OnlyCompany source
Binding Affinity Assay
High-throughput binding affinity characterization for protein designs
Service · Cloud SaaSCompany source
Expression Service
Comprehensive protein expression analysis across hundreds of variants in 2-3 weeks
Service · Cloud SaaSCompany source
Proteinbase
The home for open protein design data with standardized lab validation
Platform · Cloud SaaSCompany source
Thermostability Service
Protein thermostability characterization for design optimization
Service · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Turnaround time
2-3 weeks from sequence submission to experimental results
Binding affinity
Best binders achieved 1.11 nM (human-designed) and 3.64 nM (AI agent-designed) in TREM2 competition
Hit rate
37% binding success rate (37/100 designs) in TREM2 hackathon; 5x improvement in success rates in EGFR competition
Throughput
Thousands of proteins expressed and tested; hundreds of binding curves generated
muni × Adaptyv TREM2 Hackathon
16 teams (10 human, 6 AI agents) designed binders against TREM2 target for Alzheimer's disease in single day
37 out of 100 lab-tested designs successfully bound target; AI agents matched human teams on hit rate and binding affinity, with best human binder at 1.11 nM and best agent at 3.64 nM
University of Pennsylvania - Programmable Biology Group
Optimizing therapeutic peptides across multiple properties using MOG-DFM model with Adaptyv validation
Successfully optimized therapeutic peptides across up to 5 different properties simultaneously
BindCraft Biosensor Project
Designing modular protein sensors for maltose using BindCraft with Adaptyv validation
Successfully created de novo biosensors for maltose, proving combination of computational design and high-throughput screening can rapidly turn biological concepts into functional tools
Pro-1 FGF-1 Optimization Project
Testing FGF-1 designs using Pro-1 protein reasoning model for melting temperature improvements
Achieved significant melting temperature improvements while maintaining target binding; one design reached melting temperature comparable to most optimized FGF-1 variants in literature
Microsoft Research
Validated proteins designed by EvoDiff, Microsoft's novel sequence-first protein design model
Validated EvoDiff-generated proteins in just a few weeks using automated lab
EGFR Binder Design Competition Participants
Designed binders for EGFR target in protein design competition
5x improvement in success rates with some designs outperforming clinical antibodies
RFdiffusion IL-7Ra Binder Project
Benchmarking RFdiffusion generated binders for IL-7Ra target
Validated RFdiffusion designed binders in less than 24 hours using automated Affinity Characterization workflow
Chai Discovery
Protein design validation and testing using Adaptyv's expression workflow
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
06 · Company updates
Updates from Adaptyv Bio
Recent articles published on Adaptyv Bio's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Drug Discovery & Development
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.